Atelocollagen-mediated systemic DDS for nucleic acid medicines

Ann N Y Acad Sci. 2006 Oct;1082:9-17. doi: 10.1196/annals.1348.010.


The goal of our research is to provide a practical platform for drug delivery in oligonucleotide therapy. We report here the efficacy of an atelocollagen-mediated oligonucleotide delivery system applied to systemic siRNA and antisense oligonucleotide treatments in animal disease models. Atelocollagen and oligonucleotides formed a complex of nanosized particles, which was highly stable against nucleases. The complex allowed oligonucleotides to be delivered efficiently into several organs and tissues via intravenous administration. In a tumor metastasis model, the complex successfully delivered siRNA to metastasized tumors in bone tissue and inhibited their growth. We also demonstrated that a single intravenous treatment of the antisense oligodeoxynucleotide complex suppressed ear dermatitis in a contact hypersensitivity model. These results indicate the strong potential of the atelocollagen-mediated drug delivery system for practical therapeutic technology.

MeSH terms

  • Animals
  • Bone Neoplasms / secondary
  • Collagen / therapeutic use*
  • Dermatitis / therapy
  • Disease Models, Animal
  • Drug Carriers / chemistry*
  • Genetic Therapy / methods
  • Humans
  • Hypersensitivity / drug therapy
  • Mice
  • Mice, Nude
  • Nanoparticles
  • Neoplasm Metastasis / drug therapy
  • Oligonucleotides / administration & dosage*
  • RNA, Small Interfering / administration & dosage*
  • Tissue Distribution


  • Drug Carriers
  • Oligonucleotides
  • RNA, Small Interfering
  • atelocollagen
  • Collagen